This Journal feature begins with a case vignette that includesa therapeutic recommendation. A discussion of the clinical problemand the mechanism of benefit of this form of therapy follows.Major clinical studies, the clinical use of this therapy, andpotential adverse effects are reviewed. Relevant formal guidelines,if they exist, are presented. The article ends with the authors'clinical recommendations.
A 44-year-old woman with chronic hepatitis C has intermittentfatigue and persistent elevations in serum alanine aminotransferaselevels. She has had hepatitis C for 10 years. The diagnosiswas made after she attempted to donate blood and was found . . . [Full Text of this Article]
The Clinical Problem
Pathophysiology and Effect of Therapy
Clinical Evidence
Clinical Use
Adverse Effects
Areas of Uncertainty
Guidelines
Recommendations
Source Information
From the Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
Address reprint requests to Dr. Hoofnagle at Bldg. 31, Rm. 9A27, 31 Center Dr., National Institutes of Health, Bethesda, MD 20892, or at hoofnaglej@extra.niddk.nih.gov.
Related Letters:
Peginterferon and Ribavirin for Hepatitis C
Duggan A. E., Duggan J. M., Assy N., Embon O., Evoli A., Servidei S., Ben Salem C., Hmouda H., Bouraoui K., Leiner S., Abramowicz M., Hoofnagle J. H., Seeff L. B.
Extract |
Full Text |
PDF
N Engl J Med 2007;
356:1269-1271, Mar 22, 2007.
Correspondence
This article has been cited by other articles:
Moriya, K., Miyoshi, H., Tsutsumi, T., Shinzawa, S., Fujie, H., Shintani, Y., Yotsuyanagi, H., Moriishi, K., Matsuura, Y., Suzuki, T., Miyamura, T., Koike, K.
(2009). Tacrolimus Ameliorates Metabolic Disturbance and Oxidative Stress Caused by Hepatitis C Virus Core Protein: Analysis Using Mouse Model and Cultured Cells. Am. J. Pathol.
175: 1515-1524
[Abstract][Full Text]
Kiser, J. J.
(2009). Trends in the Treatment of Chronic Hepatitis C Virus Infection. Journal of Pharmacy Practice
22: 405-418
[Abstract]
Rotman, Y., Liang, T. J.
(2009). Coinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical Outcomes. J. Virol.
83: 7366-7374
[Full Text]
Mengshol, J A, Golden-Mason, L, Castelblanco, N, Im, K A, Dillon, S M, Wilson, C C, Rosen, H R, for the Virahep-C Study Group,
(2009). Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes. Gut
58: 964-973
[Abstract][Full Text]
Szretter, K. J., Gangappa, S., Belser, J. A., Zeng, H., Chen, H., Matsuoka, Y., Sambhara, S., Swayne, D. E., Tumpey, T. M., Katz, J. M.
(2009). Early Control of H5N1 Influenza Virus Replication by the Type I Interferon Response in Mice. J. Virol.
83: 5825-5834
[Abstract][Full Text]
Hoofnagle, J. H.
(2009). A Step Forward in Therapy for Hepatitis C. NEJM
360: 1899-1901
[Full Text]
Kugel, D., Kochs, G., Obojes, K., Roth, J., Kobinger, G. P., Kobasa, D., Haller, O., Staeheli, P., von Messling, V.
(2009). Intranasal Administration of Alpha Interferon Reduces Seasonal Influenza A Virus Morbidity in Ferrets. J. Virol.
83: 3843-3851
[Abstract][Full Text]
Di Bisceglie, A. M., Shiffman, M. L., Everson, G. T., Lindsay, K. L., Everhart, J. E., Wright, E. C., Lee, W. M., Lok, A. S., Bonkovsky, H. L., Morgan, T. R., Ghany, M. G., Morishima, C., Snow, K. K., Dienstag, J. L., the HALT-C Trial Investigators,
(2008). Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon. NEJM
359: 2429-2441
[Abstract][Full Text]
Govindarajan, R., Endres, C. J., Whittington, D., LeCluyse, E., Pastor-Anglada, M., Tse, C.-M., Unadkat, J. D.
(2008). Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol.
295: G570-G580
[Abstract][Full Text]
Yang, W., Zhao, Y., Fabrycki, J., Hou, X., Nie, X., Sanchez, A., Phadke, A., Deshpande, M., Agarwal, A., Huang, M.
(2008). Selection of Replicon Variants Resistant to ACH-806, a Novel Hepatitis C Virus Inhibitor with No Cross-Resistance to NS3 Protease and NS5B Polymerase Inhibitors. Antimicrob. Agents Chemother.
52: 2043-2052
[Abstract][Full Text]
Liu, C-H, Liang, C-C, Lin, J-W, Chen, S-I, Tsai, H-B, Chang, C-S, Hung, P-H, Kao, J-H, Liu, C-J, Lai, M-Y, Chen, J-H, Chen, P-J, Kao, J-H, Chen, D-S
(2008). Pegylated interferon {alpha}-2a versus standard interferon {alpha}-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut
57: 525-530
[Abstract][Full Text]
Cross, T J S, Antoniades, C G, Harrison, P M
(2008). Current and future management of chronic hepatitis C infection. Postgrad. Med. J.
84: 172-176
[Abstract][Full Text]
Kanda, T., Steele, R., Ray, R., Ray, R. B.
(2007). Hepatitis C Virus Infection Induces the Beta Interferon Signaling Pathway in Immortalized Human Hepatocytes. J. Virol.
81: 12375-12381
[Abstract][Full Text]
Noueiry, A. O., Olivo, P. D., Slomczynska, U., Zhou, Y., Buscher, B., Geiss, B., Engle, M., Roth, R. M., Chung, K. M., Samuel, M., Diamond, M. S.
(2007). Identification of Novel Small-Molecule Inhibitors of West Nile Virus Infection. J. Virol.
81: 11992-12004
[Abstract][Full Text]
Golden-Mason, L., Palmer, B., Klarquist, J., Mengshol, J. A., Castelblanco, N., Rosen, H. R.
(2007). Upregulation of PD-1 Expression on Circulating and Intrahepatic Hepatitis C Virus-Specific CD8+ T Cells Associated with Reversible Immune Dysfunction. J. Virol.
81: 9249-9258
[Abstract][Full Text]
Liang, T. J.
(2007). Shortened Therapy for Hepatitis C Virus Genotype 2 or 3 -- Is Less More?. NEJM
357: 176-178
[Full Text]
Duggan, A. E., Duggan, J. M., Assy, N., Embon, O., Evoli, A., Servidei, S., Ben Salem, C., Hmouda, H., Bouraoui, K., Leiner, S., Abramowicz, M., Hoofnagle, J. H., Seeff, L. B.
(2007). Peginterferon and Ribavirin for Hepatitis C. NEJM
356: 1269-1271
[Full Text]
Previous
